Code Pharma has reported promising results from an eight-week clinical study of Gammora, a novel drug aimed at targeting HIV. The findings, shared at the 2024 HIV Drug Therapy Conference in Glasgow, suggest Gammora could pave the way toward a cellular-level cure for HIV.
Gammora, derived from the HIV-1 integrase peptide, facilitates the integration of viral genetic material into infected cells’ DNA. In an open-label, randomized trial, the drug was administered alongside protease inhibitor (PI)-based antiretroviral therapy (ART). The combination not only safely reduced the HIV reservoir—the group of infected cells harboring the virus—but did so without harming surrounding healthy cells, a concern often associated with ART alone.